Apr 13 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder View
Feb 15 2017 Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference View
Jan 25 2017 Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone View
Oct 27 2016 Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention View
Oct 19 2016 Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms View
